Noopept
Also known as: N-Phenylacetyl-L-prolylglycine ethyl ester, GVS-111, Omberacetam
Effective Dosage
20 mg daily based on available clinical data
What the Science Says
Noopept is a synthetic dipeptide compound originally developed in Russia as a nootropic and neuroprotective drug. Small clinical trials in patients with stroke or traumatic brain injury suggest it may improve cognitive function and produce EEG changes consistent with nootropic activity at 20 mg daily over two months. Animal and lab studies suggest it may protect neurons from oxidative damage and glutamate toxicity, but these findings have not been confirmed in large human trials.
What It Doesn't Do
Not proven to boost cognition in healthy people. No large randomized controlled trials support its use as a general 'smart drug.' No evidence it prevents dementia or reverses age-related memory loss in healthy adults. The meteoadaptogen study in healthy volunteers was very small and measured subjective functional state, not cognitive performance. Don't assume animal study results translate to humans.
Evidence-Based Benefits
Limited clinical evidence suggests Noopept (20 mg/day for 2 months) may improve cognitive function in stroke patients with mild cognitive impairment, as measured by MMSE scores and association tests (PMID: 22500312). EEG studies in patients with post-traumatic or vascular brain injury show nootropic-consistent changes including increased alpha/beta rhythms and reduced delta rhythms, with more pronounced effects in vascular disease (PMID: 19008801). Preclinical data suggest neuroprotective properties including protection against glutamate toxicity in hippocampal neurons (PMID: 27265136) and DNA damage prevention in prediabetic mice (PMID: 31776952), but these findings have not been confirmed in human trials.
Weak EvidenceEffective at: 20 mg daily (clinical studies); animal studies used 0.5 mg/kg IP
Source: auto-research
Absorption & Bioavailability
Poor orally (~10% bioavailability reported in pharmaceutical research); transdermal and intranasal delivery routes are being explored in preclinical studies to improve absorption
Red Flags to Watch For
- Noopept is not approved as a dietary supplement or drug in the US, EU, or Australia — it is classified as an unauthorized or prescription-only substance in many jurisdictions
- A 2025 European market surveillance study found noopept frequently sold illegally, often in bulk raw material form, raising serious concerns about product safety, purity, and accurate dosing
- Nearly all human clinical data comes from small, open-label Russian studies with no placebo control, making results difficult to interpret
- Sold in 41 registered supplement products in the US despite lacking FDA approval as a supplement ingredient — consumers may not realize they are taking an unapproved drug
- Long-term safety data in humans is essentially nonexistent
Research Sources
- PubMed
- NIH DSLD
This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-04-06